GT-002 / Pentixapharm - LARVOL DELTA

Targeting of a cancer-associated LYPD3 glycoform for tumor therapy (SITC 2022) - "Notably, GT-002 elicits markedly reduced binding to normal human tissues compared to anti-LYPD3 polyclonal control antibodies or Lupartumab, an anti-LYPD3 antibody previously in clinical development as ADC (BAY1129980). By using this approach, we were able to develop an anti-LYPD3 antibody that stains cancer tissue of various indications while showing drastically reduced off-tumor binding towards healthy LYPD3-positive tissues. We believe that this highly specific antibody is exceptionally suitable for potent therapies like ADCs, radio-conjugates and CARs."

Colorectal Cancer • Esophageal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • LYPD3

Glycotope Presents GlycoTarget Platform and New Data on Platform-Derived anti-LYPD3 Antibody at 2022 Society for Immunotherapy of Cancer (SITC) Meeting (GlobeNewswire) - "Glycotope GmbH...announces that it will present new data at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held in Boston, United States, between 8-12 November 2022....'We are looking forward to providing an update on the progress of our lead antibody program, GT-002, at SITC. The glycosylation-dependent binding of LYPD3 by GT-002 leads to markedly improved tumor-selectivity compared to protein binding antibodies resulting in reduced binding to healthy tissues. In addition, we will deliver a presentation on our GlycoTarget platform, showcasing how, by utilizing the same principle, our technology can be applied to significantly improve selectivity across other targets beside LYPD3.'"

Preclinical • Oncology • Solid Tumor